Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences, Inc. (NASDAQ:XBIO) saw a large decline in short interest in July. As of July 31st, there was short interest totaling 11,313 shares, a decline of 41.4% from the July 15th total of 19,290 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average trading volume of 16,846 shares, the days-to-cover ratio is presently 0.7 days.

Xenetic Biosciences Trading Down 0.6%

XBIO opened at $3.26 on Tuesday. The company has a market cap of $7.47 million, a price-to-earnings ratio of -2.81 and a beta of 2.10. The company’s fifty day moving average price is $2.88 and its two-hundred day moving average price is $2.84. Xenetic Biosciences has a 1-year low of $1.90 and a 1-year high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last posted its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter. Xenetic Biosciences had a negative return on equity of 40.62% and a negative net margin of 75.90%.The business had revenue of $0.66 million during the quarter.

Institutional Trading of Xenetic Biosciences

A hedge fund recently raised its position in Xenetic Biosciences stock. Renaissance Technologies LLC increased its position in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 516.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 178,509 shares of the company’s stock after purchasing an additional 149,559 shares during the quarter. Renaissance Technologies LLC owned approximately 7.80% of Xenetic Biosciences worth $387,000 as of its most recent SEC filing. Institutional investors own 15.12% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.